In Depth 8 Oct 2024
Top biotech deals of September 2024
There were a number of deals that stirred the biopharma industry in September. We have listed the major collaborations that took place last month.
In Depth
- Latest Posts
In Depth 7 Oct 2024
Spinal cord injury: Are we getting closer to a treatment?
Delve into the spinal cord injury treatment landscape with a few pharmaceutical approaches that could tackle this complex condition.
In Depth 4 Oct 2024
The biggest private biotech investments in September 2024
The companies Candid Therapeutics, ArsenalBio, and eGenesis bagged the biggest private biotech investments in September 2024.
In Depth 26 Sep 2024
The radiopharmaceutical revolution: From diagnosis to treatment, oncology and beyond
Delve into the world of radiopharmaceuticals: explore their mechanisms, promising candidates, and the key players driving innovation.
In Depth 25 Sep 2024
How Pfizer’s decision in the ’90s cost them a stronghold in the GLP-1 market
Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ’90s.
In Depth 24 Sep 2024
New partnership model on the rise: how VCs are helping Pharma hunt for their next blockbuster
Discover how the recent Pfizer-Flagship alliance model sets a trend in pharma-VC partnerships, fostering innovation in drug development.
ADVERTISEMENT
ADVERTISEMENT
In Depth 20 Sep 2024
Mitigating hot flashes: new therapies for menopause on the rise
New therapies could address menopause symptoms, a field in which many treatment gaps still exist.
In Depth 19 Sep 2024
Mitochondrial disease treatments: is a breakthrough on the horizon?
Mitochondrial dysfunction is linked to many diseases. Discover how biotechs are developing mitochondrial disease treatments to address these diseases.
In Depth 18 Sep 2024
Two targets, one solution: The rise of bispecific antibodies
Find out all you need to know about bispecific antibodies, including how they work and what the current clinical landscape looks like.
In Depth 12 Sep 2024
New treatments being developed for schizophrenia
Explore the latest strides in schizophrenia treatment development as 2024 heralds a pivotal year, with promising collaborations and trials.
In Depth 5 Sep 2024
The biggest private biotech investments in August 2024
The companies Borealis Biosciences, Outpace Bio, and Halda Therapeutics bagged the biggest private biotech investments in August 2024.
In Depth 3 Sep 2024
Adaptimmune: The long road toward finally bringing the first TCR-T cell therapy to the market
Find out about Adaptimmune’s long – and somewhat bumpy – road toward bringing the first TCR-T therapy to the market.
ADVERTISEMENT
